> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Rapport Therapeutics Says $815.4 Million In Cash Funds It Through 2029 After Bipolar Mania Win
- URL: https://www.bullished.co/rapport-therapeutics-says-815-4-million-in-cash-funds-it-through-2029-after-bipolar-mania-c14ed735/
- Published: 2026-11-04T12:21:49.000Z
- Updated: 2026-11-04T12:21:49.000Z
- Description: The drug developer's third-quarter net loss grew to $40.2 million as spending on RAP-219 rose, but October financing lifted its cash position.
- Author: Matteo Parrino
- Tags: Earnings, RAPP, Industry: Healthcare

[Rapport Therapeutics](https://www.bullished.co/tag/rapp/), a clinical-stage company developing small molecule medicines for neurological and psychiatric disorders, said Wednesday it has estimated cash of [$815.4 million](https://www.sec.gov/Archives/edgar/data/0002012593/000119312526446202/rapp-ex99%5F1.htm?ref=bullished.co) and expects that to fund operations through the end of 2029\. The figure follows an October financing, while its third-quarter net loss widened to $40.2 million, or $0.84 per share, from $26.9 million, or $0.71, a year earlier.

## Bigger bills for RAP-219

Research and development spending rose to $34.3 million from $22.3 million a year earlier, the company said in an [8-K](https://www.sec.gov/Archives/edgar/data/0002012593/000119312526446202/rapp-20261104.htm?ref=bullished.co). It tied the increase to costs of the Phase 3 focal onset seizure program, the finish of the bipolar mania Phase 2 trial and wider pipeline work.

Selling, general and administrative expense was $9.8 million, versus $7.7 million, on growth in headcount and pay. Interest income was $3.9 million against $3.1 million. Rapport ended September with $395.0 million in cash, cash equivalents and short-term investments, down from $436.1 million at June 30.

## A $410.7 million financing

In October, Rapport completed a public offering of stock at $21.00 per share, with pre-funded warrants at $20.999 for some investors, plus an offering of 2.25% convertible senior notes due 2032 and a concurrent private placement of stock at the offering price. Net proceeds were about $410.7 million.

In November the company also sold roughly $10 million of stock under its at-the-market program at $25.05 per share. The $815.4 million estimate is unaudited and covers cash, cash equivalents and short-term investments: the September 30 balance plus about $420.7 million from the October and November sales.

## Bipolar mania data and the road ahead

On October 20, Rapport reported that RAP-219 met the main goal of a randomized, placebo-controlled Phase 2 trial in 253 adults with bipolar I disorder in an acute manic episode. Patients showed a 3.1-point improvement over placebo on the Young Mania Rating Scale at Week 3 (p=0.045). All treatment-emergent adverse events were mild or moderate, with no serious ones, and 3.2% of RAP-219 patients stopped treatment because of one, versus 0.8% on placebo.

CEO Abraham N. Ceesay called the results "transformational for Rapport." The company says RAP-219 now has proof-of-concept in epilepsy and bipolar mania.

Rapport plans an FDA meeting on bipolar mania trial design in the first quarter of 2027, with two Phase 3 trials expected to start in the second half of 2027\. A Phase 3 trial in primary generalized tonic-clonic seizures is expected to begin in the first half of 2027.

Initial data from the open-label long-term epilepsy safety trial are due in the fourth quarter of 2026.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — Rapport Therapeutics, Inc. (RAPP)](https://www.sec.gov/Archives/edgar/data/0002012593/000119312526446202/rapp-20261104.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit rapp-ex99\_1.htm — Rapport Therapeutics, Inc. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0002012593/000119312526446202/rapp-ex99%5F1.htm?ref=bullished.co) — SEC EDGAR

### More on Rapport Therapeutics

- [Rapport Therapeutics Closes $172.5 Million Convertible Note Sale And $21.00-A-Share Stock Offering](https://www.bullished.co/rapport-therapeutics-closes-172-5-million-convertible-note-sale-and-21-00-a-share-stock-49a05bca/)
- [Rapport Therapeutics Prices $200 Million Share Sale At $21, Below Tuesday's $27.54 Price](https://www.bullished.co/rapport-therapeutics-prices-200-million-share-sale-at-21-below-tuesdays-27-54-price-8d01d92e/)
- [Rapport's Bipolar Mania Drug Beat Placebo By 3.1 Points, But Twice As Many Quit Treatment](https://www.bullished.co/rapports-bipolar-mania-drug-beat-placebo-by-3-1-points-but-twice-as-many-quit-treatment-f4fda96c/)

[All Rapport Therapeutics (RAPP) coverage →](https://www.bullished.co/tag/rapp/)